短期生长抑素类似物试验诊断促甲状腺激素分泌性垂体腺瘤
研究在训练队列(促甲状腺激素腺瘤32例、甲状腺激素抵抗β型20例)中评估短期生长抑素类似物试验的敏感性和特异性,并在验证队列(促甲状腺激素腺瘤9例、甲状腺激素抵抗β型2例)中确认;24小时与2小时促甲状腺激素抑制比在切点44.46%时训练队列敏感性95.00%、特异性93.75%、阳性预测值88.89%。
要点
- 促甲状腺激素腺瘤患者24小时与2小时促甲状腺激素抑制比显著大于甲状腺激素抵抗β型患者。
- 24小时与2小时抑制比在切点44.46%时训练队列敏感性95.00%、特异性93.75%。
- 前瞻队列12例中3例抑制比大于44.46%,随访期间均出现微腺瘤。
核心结论
- 短期生长抑素类似物试验为促甲状腺激素腺瘤提供了一种替代诊断方法。
- 阳性的生长抑素类似物试验结果提示促甲状腺激素腺瘤,即使垂体影像学尚未出现阳性发现。
- 作者指出需要纳入更多患者尤其是甲状腺激素抵抗β型患者的研究来证实这些发现。
研究设计与样本
- 先在训练队列(促甲状腺激素腺瘤32例、甲状腺激素抵抗β型20例)中评估生长抑素类似物试验的敏感性和特异性。
- 随后在独立验证队列(促甲状腺激素腺瘤9例、甲状腺激素抵抗β型2例)中验证该试验。
- 最后将生长抑素类似物试验应用于12例前瞻性纳入的影像学阴性且无甲状腺激素受体β基因突变或混合激素失衡的不适当促甲状腺激素分泌综合征病例。
主要发现
- 促甲状腺激素腺瘤和甲状腺激素抵抗β型患者在生长抑素类似物试验开始时促甲状腺激素均下降,但甲状腺激素抵抗β型患者在2小时后促甲状腺激素抑制速度缓慢减弱。
- 24小时与2小时促甲状腺激素抑制比:促甲状腺激素腺瘤组70.58%±18.6% vs 甲状腺激素抵抗β型组6.01%±25.41%,p<0.0001。
- 24小时与0小时促甲状腺激素抑制比:促甲状腺激素腺瘤组79.83%±12.79% vs 甲状腺激素抵抗β型组51.16%±13.62%,p<0.0001。
- 训练队列中24小时与2小时抑制比在切点44.46%时诊断准确性最佳,敏感性95.00%、特异性93.75%、阳性预测值88.89%。
- 验证队列确认了该准确性;前瞻队列12例中3例促甲状腺激素抑制比大于44.46%,且随访期间均出现微腺瘤。
关键数值与推荐
- 24小时与2小时促甲状腺激素抑制比切点为44.46%。
- 训练队列中该切点的敏感性为95.00%、特异性为93.75%、阳性预测值为88.89%。
- 24小时与2小时抑制比:促甲状腺激素腺瘤组70.58%±18.6% vs 甲状腺激素抵抗β型组6.01%±25.41%,p<0.0001。
- 24小时与0小时抑制比:促甲状腺激素腺瘤组79.83%±12.79% vs 甲状腺激素抵抗β型组51.16%±13.62%,p<0.0001。
临床怎么用
- 短期生长抑素类似物试验可作为促甲状腺激素腺瘤的替代诊断方法。
- 阳性的生长抑素类似物试验结果提示促甲状腺激素腺瘤,即使垂体影像学尚未出现阳性发现。
- 作者指出需要纳入更多患者尤其是甲状腺激素抵抗β型患者的研究来证实这些发现。
局限性
- 作者指出需要纳入更多患者尤其是甲状腺激素抵抗β型患者的研究来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Diagnosis of thyrotropin (TSH)-secreting pituitary adenomas (TSHoma) before surgery remains a challenge, especially for microadenomas. We aimed to establish a short-term somatostatin analogue (SSA) test to differentiate TSHomas from other causes of syndromes of inappropriate secretion of TSH (IST), mainly resistance to thyroid hormone β (RTHβ). Materials and Methods: We first evaluated the sensitivity and specificity of SSA test in a training cohort (TSHoma, n = 32; RTHβ, n = 20). The test was then validated in an independent cohort (TSHoma, n = 9; RTHβ, n = 2). We finally applied the SSA test in 12 perceptively enrolled IST cases with negative imaging findings and absent thyroid hormone receptor beta (THRB) mutations or mixed hormone imbalances. Results: Both TSHoma and RTHβ patients showed a decrease of TSH at the start of the SSA test, but the velocity of the TSH suppression slowly decreased in RTHβ patients after 2 hours. The suppression ratio of TSH at 24 hours versus 2 and 0 hours was significantly greater in TSHoma patients compared with RTHβ patients (70.58% ± 18.6% vs. 6.01% ± 25.41%, p < 0.0001, 79.83% ± 12.79% vs. 51.16% ± 13.62%, p < 0.0001, respectively). The 24- versus 2-hour suppression ratio showed the best diagnostic accuracy at a cut point of 44.46% in the training cohort, with a sensitivity of 95.00%, a specificity of 93.75%, and a positive predictive value (PPV) of 88.89%. The accuracy was confirmed in the validation cohort. Three out of 12 patients in the prospective cohort showed a TSH suppression ratio greater than 44.46% and all developed microadenomas during follow-up. Conclusions: A short-term SSA test provides an alternative diagnostic approach for TSHomas. A positive SSA test result is suggestive for a TSHoma even before positive findings become apparent on pituitary imaging. However, studies including larger number of patients, especially those with RTHβ, are needed to confirm our findings.
引用
- Han R, Shen L, Zhang J, et al. Diagnosing Thyrotropin-Secreting Pituitary Adenomas by Short-Term Somatostatin Analogue Test. Thyroid. 2020. PMID: 32212919. doi:10.1089/thy.2019.0470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。